CNSP | CNS Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1090 - 0.1271
52 Week Range	0.0960 - 65.50
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	9,928,376
Average Volume	16,168,719
Shares Outstanding	57,486,700
Market Cap	6,605,222
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-11-08

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-299.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNSP's peers: ACHV, ALLR, ANNX, ATNF, ATXI, AVIR, CELU, ZVSA, EFTR, VECT, AVRO, IMMX, NAVB, SONN, CWBR, OCEA, ENVB, ELEV, HEPA, CYTO, IMMP, INAB, CYBN, LEXX, NBTX, NBY, PHAT, PHGE, PHIO, RCUS, RNAZ, RXRX, SNGX, CDIO, ICU, SPRY, CMND, CARM

*Chart delayed

Analyzing fundamentals for CNSP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CNSP Fundamentals page.

Watching at CNSP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CNSP Technicals page.